Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPF World Week

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

The big dilemma in international digital pharma marketing

How to get consistent international marketing while meeting local affiliates’ needs.

Anthill Agency

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

Digital transformation: What it means and how to get started

Digital transformation is one of those things that everyone seems to be talking about, yet no one really knows how to do it – or even what it is. So...

Anthill Agency

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

- PMLiVE

The real-world data conundrum

How data is changing the healthcare industries

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

Roche Basel Switzerland

New data could unlock bigger market for Roche’s Hemlibra

Trial shows it ‘significantly’ reduced bleeds in some haemophilia A patients

Roche acquires US laboratory big data company Viewics

Gains cloud-based laboratory business analytics capabilities

Roche Basel Switzerland

Roche gets first approval for haemophilia A therapy

The first-in-class therapy wins US marketing licence three months earlier than expected

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links